Back to results
US 2010/0063064 A1Published application
Substituted Triazole Derivatives As Oxytocin Antagonists
AssigneePfizer Inc.
InventorsAlan Daniel Brown, David Ellis, Christopher Ronald Smith
Life of this patent
Estimating the term…
Abstract
The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).
Claims24
A compound of formula (I)
- wherein
- X and Y are each N;
- V and W are each C—R6;
- Z is C—H or N;
- R1 is selected from:
- (i) a phenyl ring substituted with two or more substituents, which may be the same or different, each independently selected from halo, (C1-C6)alkyl, (C1-C6)alkoxy, cyano, C(O)NR7R8, NR7R8, NR7C(O)R10 and N[C(O)R10]2;
- and
- (ii) a five to seven membered aromatic heterocyclic ring containing 1-3 hetero atoms selected from N, O and S and N-oxides thereof;
- said ring being optionally substituted with two or more substituents, which may be the same or different, selected from halo, (C1-C6)alkyl, (C1-C6)alkoxy, cyano, C(O)NR7R8, NR7R8, NR7C(O)R10 and N[C(O)R10]2;
- R2 is selected from:
- (i) H, OH, OR9, NR7R8, NR7C(O)R10 and N[C(O)R10]2;
- (ii) a 5-7 membered N-linked heterocycle containing 1-3 heteroatoms selected from N, O and S;
- said ring being optionally substituted with one or more groups selected from (C1-C6)alkyl, (C1-C6)alkoxy and C(O)NR7R8;
- and
- (iii) (C1-C6)alkyl optionally substituted with an N-linked 5-7 membered heterocycle containing 1-3 heteroatoms selected from N, O and S;
- R3 is selected from H and (C1-C6)alkyl;
- R4 is selected from H, (C1-C6)alkyl and OR9;
- R5 is selected from halo, (C1-C6)alkyl, (C1-C6)alkoxy, NR7R8, NR7C(O)R10 and N[C(O)R10]2;
- R6 is selected from H, halo, (C1-C6)alkyl, (C1-C6)alkoxy, cyano, NR7R8, NR7C(O)R10, N[C(O)R10]2 and C(O)NR7R8;
- R7 and R8, which may be the same or different, are selected from H and (C1-C6)alkyl;
- R9 is (C1-C6)alkyl, which is optionally substituted with one or more groups each independently selected from (C1-C6)alkoxy and an N-linked 5-7 membered heterocycle containing 1-3 heteroatoms selected from N, O and S;
- and
- R10 is selected from (C1-C6)alkyl and (C1-C6)alkoxy;
- or a pharmaceutically acceptable salt;
- thereof.
22 more elements
(canceled)
(canceled)
(canceled)
-21. (canceled)
(canceled)
-26. (canceled)
Dependencies are inferred from the claim text.